Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 2Gastrointestinal Neoplasms 1Fatigue 1Cognitive Dysfunction 1

Interventions

Surveys and Questionnaires 7Nivolumab 5atezolizumab 3Radiosurgery 3Blood Specimen Collection 3pertuzumab 2pembrolizumab 2pazopanib 2cemiplimab 2amminedichloro(2-methylpyridine)platinum(II) 2alectinib 2Magnetic Resonance Spectroscopy 2Interviews as Topic 2Drug Therapy 2Capecitabine 2tepotinib 1talazoparib 1selpercatinib 1pralsetinib 1ponatinib 1pemigatinib 1palbociclib 1motexafin gadolinium 1montanide ISA 51 1mannide monooleate 1itacitinib 1ipatasertib 1fludarabine 1entrectinib 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × Methylphenidate × Breast × Clear all
NCT00516269 2018-01-03

Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients

M.D. Anderson Cancer Center

Phase 3 Terminated
42 enrolled 8 charts
BreastGastrointestinal

Breast Neoplasms, Fatigue, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡